Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 4

Tobacco smoking cessation management: integrating varenicline in current practice

Authors Laurence M Galanti

Published Date September 2008 Volume 2008:4(4) Pages 837—845

DOI http://dx.doi.org/10.2147/VHRM.S3250

Published 5 September 2008

Laurence M Galanti

Clinique Universitaire UCL, Mont-Godinne, Yvoir, Belgium

Abstract: Tobacco smoking is widespread and is one of the world’s most prevalent modifiable risk factors for morbidity and mortality. It is important to facilitate smoking cessation better in order to reduce the health consequences of tobacco use. The most effective approach assisting smokers in their quit attempts combines both pharmacotherapy and nonpharmacological interventions. This review summarizes the latest international epidemiological data available on tobacco use, considers the associated effects on health, and reviews existing policies against tobacco use. Among the interventions for smoking cessation, the three major pharmacotherapies (which have demonstrated efficacy when combined with behavioral support) are discussed: nicotine replacement therapy (NRT), bupropion, and varenicline. As the newest pharmacotherapy made available in this area, particular consideration is given to varenicline, and a review of our clinical experience is offered.

Keywords: tobacco smoking cessation, nicotinic substitution, nicotine replacement therapy (NRT), bupropion, varenicline

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Prevalence of drug resistance and culture-positive rate among microorganisms isolated from patients with ocular infections over a 4-year period

Shimizu Y, Toshida H, Honda R, Matsui A, Ohta T, Asada Y, Murakami A

Clinical Ophthalmology 2013, 7:695-702

Published Date: 9 April 2013

New type of antidrying lens for vitreous surgery with a noncontact wide-angle viewing system

Chihara T, Kita M

Clinical Ophthalmology 2013, 7:353-355

Published Date: 15 February 2013

Increased reactive oxygen metabolites is associated with cardiovascular risk factors and vascular endothelial damage in middle-aged Japanese subjects

Sugiura T, Dohi Y, Takase H, Yamashita S, Tanaka S, Kimura G

Vascular Health and Risk Management 2011, 7:475-482

Published Date: 19 July 2011

Depression in vascular pathologies: the neurologist's point of view

Moretti R, Bernobich E, Esposito F, Torre P, Antonello RM, De Angelis L, Bellini G

Vascular Health and Risk Management 2011, 7:433-443

Published Date: 12 July 2011

Therapeutic implications of transesophageal echocardiography after transthoracic echocardiography on acute stroke patients

Tiago Tribolet de Abreu, Sonia Mateus, Cecilia Carreteiro, Jose Correia

Vascular Health and Risk Management 2008, 4:167-172

Published Date: 6 March 2008

Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure

Melvin R Echols, Clyde W Yancy

Vascular Health and Risk Management 2006, 2:423-431

Published Date: 1 March 2006

Optimal lipid modification: the rationale for combination therapy

James M Backes, Cheryl A Gibson, Patricia A Howard

Vascular Health and Risk Management 2005, 1:317-331

Published Date: 25 January 2005